Veteran European Sales Manager of Endovascular Aneurysm Repair Market
with Extensive Clinical and UK Experience
OXFORDSHIRE, England--(BUSINESS WIRE)--Sep. 20, 2017--
Lombard Medical, Inc. (NASDAQ: EVAR), a developer, manufacturer and
marketer of endovascular aortic aneurysm repair products, today
announced the appointment of Jonathan Hornsby as Vice President, Sales &
Marketing, effective immediately.
Jonathan Hornsby brings over 20 years of experience in the endovascular
aortic repair business. He has been instrumental in several product
launches, including Medtronic’s Endurant stent graft and Endologix’
Nellix endovascular aneurysm sealing system. He joins Lombard from
Endologix (NASDAQ: ELGX) where he served as Sales Director and European
Aortic Therapy Director. Prior to his five years at Endologix, Hornsby
spent 12 years in Medtronic’s endovascular business.
Kurt Lemvigh, Chief Executive Officer, commented, “Jonathan is a
world-class executive and a welcome addition to our team. He brings a
combination of extensive endovascular clinical and UK market knowledge
to Lombard. We anticipate he will greatly strengthen our direct sales
efforts in the UK and will be a valuable asset in support of our
international distribution activities.”
Hornsby stated, “This role is a great opportunity for me to be part of
an agile company with a vision to capitalize on the emerging Asian
markets and other international geographies. The fact that we are
UK-based provides our local customers with an opportunity to actually
see the product being manufactured and engage with our workforce. I’m
delighted to become part of this committed team.”
About Lombard Medical, Inc.
Lombard Medical, Inc., based in Oxfordshire, U.K., develops,
manufactures and markets an innovative range of minimally invasive
abdominal aortic aneurysm endovascular repair products. For more
information, please visit www.lombardmedical.com.
This announcement contains forward-looking statements that reflect the
Company’s current expectations regarding future events. These
forward-looking statements generally can be identified by the use of
words or phrases such as “believe,” “expect,” “future,” “anticipate,”
“look forward to,” “intend,” “plan,” “foresee,” “may,” “should,” “will,”
“estimates,” “outlook,” “potential,” “optimistic,” “confidence,”
“continue,” “evolve,” “expand,” “growth” or words and phrases of similar
meaning. Statements that describe objectives, plans or goals also are
forward-looking statements. Forward-looking statements are subject to
risks, management assumptions and uncertainties. Actual results could
differ materially from those projected herein and depend on a number of
factors, including the success of the Company’s research and development
and commercialization strategies, the uncertainties related to the
regulatory process and the acceptance of the Company’s products by
hospitals and other medical professionals, the uncertainty of estimated
revenues and profits, the uncertainty of current domestic and
international economic conditions that could adversely affect the level
of demand for the Company’s products and increased volatility in foreign
exchange rates, the inability to raise additional funds, and the risks,
uncertainties and other factors described under the heading “Risk
Factors” in the Company’s Form 20-F filed with the Securities and
Exchange Commission dated May 1, 2017. Readers are urged to consider
these factors carefully in evaluating the forward-looking statements.
The forward-looking statements included herein are made only as of the
date of this report and the Company undertakes no obligation to update
these statements in the future.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170920005077/en/
Source: Lombard Medical, Inc.
Lombard Medical, Inc.
Kurt Lemvigh, +44 (0)1235 750 800